|This Slide: #65 of 83|
Slide #65. Cubist Pharmaceuticals, Inc. — Adynxx
Cubist Pharmaceuticals, Inc. (CBST)
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) and Adynxx, Inc. announced today that they have entered into an option agreement under which Cubist has the exclusive right to acquire Adynxx following the data readout of Adynxx's Phase 2 trial for its lead product candidate, AYX1.
Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat patients who are hospitalized or are being treated in other acute care settings. Co. has three marketed products: CUBICIN® for the treatment of certain Gram-positive bacteria and for certain bloodstream infections; DIFICID® for the treatment of Clostridium difficile-associated diarrhea (CDAD); and ENTEREG® to accelerate gastrointestinal recovery. Co. has four late-stage product candidates: Tedizolid phosphate and Ceftolozane/tazobactam for treatment of Gram-positive bacterial infections; Surotomycin for CDAD; and Bevenopran for opioid-induced constipation.
Open the CBST Page at The Online Investor »
Hold (1.96 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite